Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Promising Cystic Fibrosis Compound on Track for Development
August 31st, 2007
Gilead Sciences, Inc., one of the world's largest biopharmaceutical companies, and Parion Sciences, Inc., a development-stage pharmaceutical company, announced they will co-develop Parion 680, a compound that could become an important new drug in treating the basic defect in cystic fibrosis. This product was identified as part of a $1.7 million award to Parion from Cystic Fibrosis Foundation Therapeutics, Inc. -- the CF Foundation's nonprofit drug discovery and development affiliate. "This news validates our 'venture philanthropy' approach to drug development," said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. "We are a small disease, but...
Source: Drug Week (2007-08-31)
|
